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Abstract 
The importance of an increase in serum creatinine, traditionally considered as worsening renal 
function (WRF), during an admission for acute heart failure (AHF) has been recently debated, 
with data suggesting an interaction between congestion and creatinine changes.  
Methods and results: In a post-hoc analysis, we analysed the association of WRF with length of 
hospital stay, 30-day death or cardiovascular (CV)/renal re-admission and 90-day mortality in 
the PROTECT study. Daily creatinine changes from baseline were categorized as representing 
WRF (an increase of 0.3 mg/dL or more) or not. Congestion scores were computed for each 
study day by summing the coded values of orthopnea, edema and jugular venous pressure. Of the 
2033 total patients randomized, 1537 patients had both available at study day 14. Length of stay 
(LOS) was longer and 30-day CV/Renal readmission or death was more common in patients with 
WRF. However, these were driven by significant associations in patients with concomitant 
congestion at the time of assessment of renal function.  The mean difference in LOS due to WRF 
was 3.51 (95% CI 1.29-5.73) more days (p=0.0019), and the hazard ratio for WRF on 30-day 
death or HF hospitalization was 1.49 (95% CI 1.06-2.09) times higher (p=0.0205), in 
significantly congested than non-significantly congested patients . A similar trend was observed 
with 90-day mortality although this did not reach statistical significance.   
  
Conclusions: In patients admitted for AHF, WRF as determined by a creatinine increase of ≥0.3 
mg/dL was associated with longer LOS, and worse outcomes at 30 and 90 days. However, these 
effects were largely driven by patients who had residual congestion at the time of renal function 
assessment.  
  
Introduction 
Both an increase in serum creatinine of ≥0.3 mg/dL, traditionally defined as worsening of 
renal function (WRF), and persistent congestion have been shown to be associated with adverse 
outcomes in patients admitted for acute heart failure (HF) (1-11). Further analyses have shown 
the importance of decongestion, measured either through clinical signs (12) or by laboratory 
exams, hemoconcentration or diuretic response, (13-15) as a major predictor of outcomes. 
Evidence has also clarified that the clinical significance of an increase in serum creatinine differs 
when it occurs concomitantly with decongestion, rather than in the presence of diuretic 
resistance. (12, 16). Lastly, retrospective analyses of randomized controlled trials have shown 
that a reduction, rather than an increase, in serum creatinine can be associated with worse 
outcomes (17-20). These last trials were characterized, however, by the enrolment of patients 
with severe heart failure so that a decrease in serum creatinine could have been an index of 
increased central venous pressure and renal venous congestion at baseline. These results further 
emphasise that the interpretation of serum creatinine changes is critically dependent on the 
patient’s fluid status. Hence, the term “pseudo-WRF” has been proposed to define when an 
increase in serum creatinine is not associated with worsening of renal function and poorer 
outcomes. (21)   
The PROTECT study was one of the first trials to apply serial measurements of creatinine 
in all patients from admission to day 6 or 7 and then at day 14 regardless of disease severity (22, 
23). Analysis of data from this study has shown that creatinine changes over time, assessed as 
“trajectories” of change, are associated with risks of both 180-day mortality and 60-day mortality 
or readmission. Namely, an increase in serum creatinine >0.1 mg/dL per day was predictive of an 
increased risk of death, whereas stable or decreasing serum creatinine levels were associated 
  
with reduced risk (24). These analyses seemingly contradict previous data. However, they may 
be caused by differences in fluid status and response to treatment. In the current post-hoc 
analysis of the PROTECT data we have assessed the prognostic significance of serum creatinine 
changes as related with the presence of congestion in patients enrolled in PROTECT. 
 
Methods 
The Placebo-controlled Randomized study of the selective A1 adenosine receptor 
antagonist rolofylline for patients hospitalized with acute decompensated heart failure and 
volume Overload to assess Treatment Effect on Congestion and renal funcTion (PROTECT) was 
a randomized, double-blind, placebo-controlled trial designed to evaluate three daily 4-hour 
intravenous infusions of rolofylline in 2033 patients hospitalized with acute decompensated heart 
failure (ADHF) and mild to moderate renal impairment (20-80 mL/min) (11,12). The study was 
initiated as two identical trials (PROTECT-1 NCT00328692 and PROTECT-2 NCT00354458), 
but shortly after amended to specify a combined analysis of the two studies. Patients at centers in 
North America, Israel, Europe, Argentina, and Russia were enrolled between May 2007 and 
January 2009.   ADHF was defined as dyspnea at rest or with minimal exertion and at least one 
sign of fluid overload: jugular venous pulse > 8 cm, pulmonary rales ≥⅓ up the lung fields not 
clearing with cough, or ≥2+ peripheral or presacral edema.  Patients with B-type natriuretic 
peptide (BNP) < 500 pg/mL or N-terminal-pro-BNP < 2000 pg/mL, or systolic blood pressure 
<95 or >160 mmHg were excluded. Patients were randomized within 24 hours of hospital 
presentation.  The ethics committee at each participating center approved the protocol, and all 
patients provided written informed consent. 
  
Signs and symptoms of HF were assessed prior to study drug initiation (day 1), then daily 
while hospitalized through day 6, and then on days 7 and 14.  Blood samples for central 
laboratory haematology and chemistry measures were taken at the same time points. Patients 
discharged on day 6 were not required to return at day 7.  Patients were contacted by telephone at 
days 60 and 180.  Rehospitalisation and deaths through day 60 were adjudicated by a blinded 
clinical events committee. The study treatment did not have a statistically significant effect on 
the study’s primary efficacy endpoint – an ordered trichotomy defined as treatment success 
(based on dyspnea relief), no change (neither success nor failure), or treatment failure (death, HF 
readmission or in-hospital WHF, or persistent worsening renal function) – at day 7.  Study 
treatment groups also did not differ with respect to either secondary efficacy endpoint – 60-day 
death or rehospitalisation for cardiovascular or renal reason or persistent renal impairment 
(creatinine increase ≥ 0.3 mg/dL at days 7 and 14) – or with respect to 180-day all-cause 
mortality.   
 
Statistical methods 
As no difference between the rolofylline and placebo treatment groups was found with respect to 
any outcome, including WRF (12, 25), the data of all patients, irrespective of drug assignment, 
are used in the present study.  
Daily creatinine changes from baseline were categorized as representing WRF (an 
increase ≥0.3 mg/dL) or not. Congestion scores were computed for each study day by summing 
up the coded values of orthopnea (0= None, 1= 1 pillow, 2= 2 pillows, 3= >30°), edema (0= 0, 
1= 1+, 2= 2+, 3= 3+), and jugular venous pressure (0= <6 cm, 1= 6-10 cm, 2= >10 cm), if all 
three parts were available, and were then dichotomized as mild (≤2) or significant (≥3) for each 
  
study day, as previously described (26) and modified for this study (Rubio-Gracia 2016, 
unpublished). Because patients discharged on day 6 were not required to return at day 
7,creatinine changes and congestion scores at day 7 were used if available and the day 6 value 
otherwise. 
Patients were subdivided into four groups defined by the occurrence or not of a creatinine 
increase ≥ 0.3 mg/dL and by the presence or absence of a congestion score ≥ 3 at two time points 
– day 2 (24-48 hours from hospital presentation) and day 14. Groups were compared regarding 
baseline characteristics using ANOVA (or Kruskal-Wallis test if highly skewed) for continuous 
variables and chi-square test for categorical variables.   
The associations with clinical outcomes of a creatinine increase ≥ 0.3 mg/dL at each 
study day were then evaluated by the dichotomized congestion score at the same study day.  A 
sensitivity analysis was conducted where congestion scores from the previous day were coupled 
with the creatinine changes from days 3 through 6 or 7. Clinical outcomes included the time to 
all-cause death or cardiovascular/renal (CV/RF) rehospitalisation from the respective study day 
through 30 days thereafter, time to all-cause death from baseline through study day 90, and 
length of initial hospital stay (LOS) through study day 60 with in-hospital deaths set to a value of 
61 days. Subjects who were not followed up beyond (>) the respective study day were excluded 
from the estimated association for that particular study day. For LOS, subjects who did not stay 
in hospital beyond the respective study day were also excluded. Associations, expressed as 
hazard ratios or mean differences respectively, were estimated using Cox proportional hazards 
models for time-to-event endpoints and linear regression models for LOS. Because LOS was 
truncated in many cases, a sensitivity analysis was performed using Cox regression for time to 
discharge through day 60. For each study day, the models included dichotomized creatinine 
  
change, dichotomized congestion score, and their interaction as factors, from which, the effects 
(hazard ratios or mean differences) of a creatinine increase ≥0.3 mg/dL were estimated for 
subjects with and without significant congestion at each study day.  Models were further adjusted 
for predictors as previously published for similar endpoints in PROTECT (27,28). Missing 
baseline parameters were imputed by multiple imputation with 10 imputed data sets assuming 
multivariate normality. Estimated effect sizes, 95% confidence intervals, and p-values were 
combined across the multiply-imputed datasets using Rubin’s algorithm (29).  
Linear regression models were used to examine whether the difference in association of 
creatinine increase with outcomes in patients with and without significant congestion varied over 
time, and to obtain an estimate of the average difference in association over time, reported as the 
average ratio of the HRs or average difference of the mean differences between these effects 
over the study period.  Variances for the estimated associations of creatinine increase with 
outcomes (log hazard ratios or mean differences) in patients with and without significant 
congestion on each study day were obtained by running the models for 1000 bootstrap samples. 
The bootstrap estimates of the creatinine increase effect were then analysed in a single linear 
regression model using the bootstrap variances and including dichotomized congestion score, 
study day, and the interaction of congestion score and study day as factors. If the interaction of 
congestion and time was non-significant, the interaction term was removed from the model, and 
the difference in the effects of creatinine increase in patients with and without significant 
congestion estimated from the bootstrap results. The same analyses were conducted examining a 
creatinine decrease ≥ 0.3 mg/dL. Two-sided p<0.05 was considered statistically significant, 
without adjustment for multiple comparisons.  SAS® 9.3 (SAS Institute, Cary, NC, USA) was 
used for analyses.   
  
 
Results 
Of the 2033 total patients randomized, 1684 patients had both creatinine change and 
congestion score available at study day 2, and 1537 patients had both available at study day 14. 
Baseline characteristics by creatinine increase and congestion score at days 2 and 14 are shown 
in Tables 1 and 2, respectively.   
Patients with a creatinine increase of >0.3 mg/dL were more likely to have an event of 
death or CV/RF readmission within 30 days of the assessment if they were significantly 
congested at the time of assessment. Figure 1 presents multivariable-adjusted hazard ratios for a 
creatinine increase in patients with and without significant congestion based on estimates from 
individual models per study day (Supplemental Table 1a), with linear regression results from the 
bootstrap analysis overlaid. In the patients with a congestion score of ≤2, the increase in serum 
creatinine was never associated with worse outcomes within 30 days of the assessment;  the HR 
estimated at day 7 from the bootstrap regression was 0.98 (95% CI 0.76-1.27, p=0.8833). In 
contrast, the increase in creatinine in the patients with significant congestion was associated with 
an almost 1.5-times higher risk of events and these hazard ratios were statistically significant 
with the measurements taken at days 2, 4 and 5 (the lower bound of the CI does not include 1.00) 
and nearly significant at the other time points (the lower 95% confidence bound was 0.97 at day 
7 and 0.96 at day 14). The HR estimated at day 7 from the bootstrap regression was 1.46 (95% 
CI 1.12-1.90, p=0.0046) with a ratio of HRs in patients with congestion score ≥3 versus not of 
1.49 (95% CI 1.06-2.09, p=0.0205). The effect of congestion on the association of creatinine 
increase with the 30-day outcome did not vary significantly over time; the ratio of HRs for a 
creatinine increase in patients with and without significant congestion remained constant from 
  
day 2 (24 hours from randomization) through day 14 (congestion-by-time interaction p=0.9100).  
Results were similar if patients were categorized by the congestion score on the day prior to the 
creatinine measurement (Supplemental Table 1b, Supplemental Figure 1); the HR for a 
creatinine increase in patients with a congestion score ≥3 the previous day was 1.39 times the 
HR in those with score ≤2 (95% CI 0.94-2.05, p=0.1020). 
With respect to mortality at 90 days, a creatinine increase of >0.3 mg/dL was associated 
with a higher risk of the outcome in patients significantly congested at the time of creatinine 
measurement (estimated at day 7 from the bootstrap linear regression: HR 1.94, 95% CI 1.43-
2.63, p<0.0001) than in those with no or mild congestion (estimated at day 7 from the bootstrap 
linear regression: HR 1.36, 95% CI 0.94-1.96, p=0.1075), although the difference did not reach 
statistical significance (ratio of HRs 1.43, 95% CI 0.92-2.23, p=0.1121) (Figure 2, Supplemental 
Table 2a). Also in this case, the modifying effect of congestion did not vary over time, as 
indicated by a non-statistically-significant congestion-by-time interaction in the bootstrap linear 
regression (p=0.2704). Similar results were observed when evaluating modification of the 
creatinine increase by the previous day’s congestion score (ratio of HRs 1.35, 95% CI 0.75-2.43, 
p=0.3121) (Supplemental Table 2b, Supplemental Figure 2). 
A creatinine increase of >0.3 mg/dL was associated with a longer length of hospital stay 
especially when noted later during the admission (Figure 3, Supplemental Table 3a). Also in this 
case, the effect of a creatinine increase differed significantly by whether the patient had 
significant congestion at the time of assessment. Patients with 0-2 congestion score did not 
experience an appreciable increase in the LOS associated with a creatinine increase ≥0.3 mg/dL 
on any day through day 7 (Supplemental Table 3a); the mean change in LOS estimated at day 7 
from the bootstrap linear regression (Figure 3) was 1.13 (95% CI -0.82-3.07) days (p=0.2564). 
  
Patients with a congestion score of ≥3 had on average a 3-day greater estimated mean difference 
in LOS for a creatinine increase ≥0.3 mg/dL; the mean change in LOS estimated at day 7 from 
the bootstrap linear regression was 4.64 (95% CI 1.87-7.41) days (p=0.0010). Again, the 
modifying effect of congestion on the effect of a creatinine increase did not change over time for 
this endpoint (congestion-by-time interaction p=0.1879), with an estimated mean difference 
between patients with and without significant congestion of 3.51 (95% CI 1.29-5.73) days 
(p=0.0019).  Similar patterns were observed when patients were categorized by the previous 
day’s congestion score (Supplemental Table 3b, Supplemental Figure 3a).  Analysis of the 
outcome as time to discharge through day 60, rather than as a continuous variable, supports this 
finding. A creatinine increase was associated with less likelihood of discharge through day 60 
only in patients significantly congested at the time (Supplemental Table 3c, Supplemental Figure 
4). 
We repeated the same analysis examining the effect of a creatinine decrease of ≥ 0.3 
mg/dL. Few patients experienced a creatinine decrease of such magnitude; at day 2, only 23 
patients with congestion score 0-2 and 72 patients with congestion score 3 experienced such a 
creatinine decrease.  Patients with a creatinine decrease at nearly all time points examined 
experienced lower rates of all three outcomes of interest (30-day CV/renal readmission or death, 
90-day death, and LOS), with the estimated beneficial effects of a creatinine decrease more 
pronounced in patients with congestion score of 3 or more; however, as the numbers of patients 
were small in these subgroups the estimated effects of a creatinine decrease, differences in 
creatinine decrease effects between patients with and without significant congestion, and any 
variation in the difference between congestion groups with respect to the creatinine decrease 
effect over time all failed to reach statistical significance (Supplemental Figures 4-6).  
  
 
Discussion 
This analysis of PROTECT shows that an increase in serum creatinine is associated with poorer 
outcomes only in the patients with significant congestion, defined as a score of 3 or more, at the 
time of the serum creatinine measurements. The difference in the effect of serum creatinine 
increases by congestion score was significant for the composite outcome at 30 days but did not 
reach statistical significance when day 90 mortality was considered, likely because of 
insufficient events. This differential effect of a creatinine increase did not vary with respect to 
the time of the clinical assessment. Similar to outcomes, LOS was longer in those patients with 
an increase in serum creatinine and concomitant congestion but not in those with a congestion 
score of 0-2. 
The clinical significance of serum creatinine changes in AHF is still controversial with either its 
increase or a reduction associated with poorer outcomes (21). Some of this heterogeneity of 
result may relate to the fact that when single time points are compared to the baseline 
assessments or the assessments are done using specific cut-offs, the result can  be less significant 
(supllemental tables 1-3). We have previously shown using a single centre database that the 
importance of creatinine changes is influenced by the fluid status (12). However, this study was 
small and relied on creatinine measurements that were not uniformly performed at pre-defined 
time points. In the current post-hoc analysis of the PROTECT data base, we confirm and expand 
these findings. First, creatinine increases of ≥0.3 mg/dl are associated with adverse outcomes 
mainly in patients who are significantly congested at the time of creatinine measurement. This 
finding would suggest that creatinine “bumps” due to excessive dehydration, such as following 
diuretic therapy, do not necessarily carry negative prognostic implications while similar 
  
increases in patients who have persistent congestion despite diuretic therapy, and who are likely 
diuretic resistant, are ominous signs. This finding is in line with clinical “common wisdom” and 
previous studies suggesting that patients who remain congested and display deterioration in renal 
function despite optimal therapy during an AHF admission, have a direr prognosis, especially 
when it comes to short-term events (12,13,21,30).  
An interaction between the effect of increases in serum creatinine and congestion on LOS was 
also found in the present analysis. Patients congested at the time of serum creatinine 
measurements had very large increases in LOS, while little to no increase in LOS occurred in 
patients who were not significantly congested at the time of their measurements. These data are 
consistent with the poorer outcomes associated with WRF in the patients who develop worsening 
heart failure, and hence congestion, during hospitalization. They also confirm the finding that 
creatinine changes significantly affect the clinical course and outcomes of patients with AHF 
only when associated with significant congestion. This finding may have implications in 
analyzing results of intervention clinical studies, as the assumption that all creatinine increases 
are associated with worse outcome may not be true, and hence some creatinine changes in 
response to interventions may not be signifiers of future adverse outcome.   
In the current analysis we did not observe an association between creatinine decreases and more 
adverse outcomes, a finding shown in other studies (17,20). To the contrary, we noted 
numerically smaller hazards for 30-day death or CV/renal readmission and 90-day mortality and 
shorter LOS in those patients. However, as noted above, only few patients had creatinine 
decreases of 0.3 mg/dL or more and none of the associations examined reached statistical 
significance. As with increases in creatinine, the difference between our data and those 
previously published may be due to chance – as none of these effects were statistically 
  
significant – or due to ascertainment bias in other studies. In PROTECT, creatinine was 
measured daily systematically and hence there was no bias towards sicker patients having more 
creatinine measurements, enabling, possibly, a more objective assessment of the associations 
between creatinine changes and adverse outcomes and their interactions with congestion.  
 
Limitations 
The current analysis is a post-hoc analysis of the PROTECT study and as such should be 
regarded with caution and should be confirmed in larger prospective studies.  Congestion scores 
were determined using a simple method. It is possible that the result would have benefited from 
better quantitative methods of congestion assessment. Analyses of the associations of creatinine 
increases with outcomes over time in patients with and without significant congestion were 
conducted on group-level data and might not be representative of individual patient trajectories. 
 
Conclusions 
In this post-hoc analysis of the PROTECT study, creatinine increases of 0.3 mg/dL or more were 
found to be associated with longer length of admission and higher risk of death or readmission 
for cardiovascular or renal reason within 30 days only in patients who at the time of creatinine 
measurement were significantly congested.  
 
 
 
 
References 
  
1. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal 
insufficiency are independent risk factors for death among patients with congestive heart 
failure admitted to community hospitals: a population-based study. J Am Soc Nephrol. 
2002; 13: 1928-36. 
2. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, 
Califf RM, Stevenson LW, Hill JA. Cardiorenal interactions: insights from the ESCAPE 
trial. J Am Coll Cardiol. 2008; 51: 1268-74. 
3. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J; 
ADHERE Scientific Advisory Committee and Investigators. High prevalence of renal  
dysfunction and its impact on outcome in 118,465 patients hospitalized with acute 
decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007; 13: 
422-30. 
4. Klein L, Massie BM, Leimberger JD, O'Connor CM, Piña IL, Adams KF Jr, Califf RM, 
Gheorghiade M; OPTIME-CHF Investigators. Admission or changes in renal function 
during hospitalization for worsening heart failure predict postdischarge survival: results 
from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of 
Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail. 2008; 1: 25-33. 
5. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie 
BM, Rich MW, Stevenson LW, Young JB, Krumholz HM. Incidence, predictors at 
admission, and impact of worsening renal function among patients hospitalized with heart 
failure. J Am Coll Cardiol 2004; 43: 61–7. 
6. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, 
Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei CL. Worsening 
  
renal function in patients hospitalized for acute heart failure: clinical implications and 
prognostic significance. Eur J Heart Fail. 2008; 10: 188 –195. 
7. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van 
Veldhuisen DJ, Hillege HL. Worsening renal function and prognosis in heart failure: 
systematic review and meta-analysis. J Card Fail. 2007; 13: 599-608. 
8. Breidthardt T, Socrates T, Noveanu M, Klima T, Heinisch C, Reichlin T, Potocki M, 
Nowak A, Tschung C, Arenja N, Bingisser R, Mueller C. Effect and clinical prediction of 
worsening renal function in acute decompensated heart failure. Am J Cardiol. 2011; 107: 
730-5. 
9. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B. Prevalence and 
impact of worsening renal function in patients hospitalized with decompensated heart 
failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 
2006; 27: 1216–22. 
10. Lanfear DE, Peterson EL, Campbell J, Phatak H, Wu D, Wells K, Spertus JA, Williams 
LK. Relation of worsened renal function during hospitalization for heart failure to long-
term outcomes and rehospitalization. Am J Cardiol. 2011; 107: 74-8. 
11. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL.  
Renal impairment, worsening renal function, and outcome in patients with heart failure: 
an updated meta-analysis. Eur Heart J. 2014; 35: 455-69.  
12. Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, Piovanelli B, Carubelli 
V, Bugatti S, Lombardi C, Cotter G, Dei Cas L. Is worsening renal function an ominous 
prognostic sign in patients with acute heart failure? The role of congestion and its 
interaction with renal function. Circ Heart Fail. 2012; 5: 54-62. 
  
13. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of 
aggressive decongestion during the treatment of decompensated heart failure on renal 
function and survival. Circulation. 2010; 122: 265-72.  
14. Testani JM, Brisco MA, Chen J, McCauley BD, Parikh CR, Tang WH. Timing of 
hemoconcentration during treatment of acute decompensated heart failure and subsequent 
survival: importance of sustained decongestion. J Am Coll Cardiol.2013; 62: 516-24.  
15. Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O'Connor CM, 
Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, 
Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL. Diuretic response in acute heart 
failure: clinical characteristics and prognostic significance. Eur Heart J. 2014; 35: 1284-
93.  
16. Voors AA, Davison BA, Teerlink JR, Felker GM, Cotter G, Filippatos G, Greenberg BH, 
Pang PS, Levin B, Hua TA, Severin T, Ponikowski P, Metra M. RELAX-AHF 
Investigators. Diuretic response in patients with acute decompensated heart failure: 
characteristics and clinical outcome--an analysis from RELAX-AHF. Eur J Heart Fail. 
2014; 16: 1230-40. 
17. Testani JM, McCauley BD, Chen J, Coca SG, Cappola TP, Kimmel SE. Clinical 
characteristics and outcomes of patients with improvement in renal function during the 
treatment of decompensated heart failure. J Card Fail. 2011;17:993–1000;  
18. Brisco MA, Coca SG, Chen J, Owens AT, McCauley BD, Kimmel SE, et al. Blood urea 
nitrogen/creatinine ratio identifies a high-risk but potentially reversible form of renal 
dysfunction in patients with decompensated heart failure. Circ Heart Fail. 2013;6:233–9;  
  
19. Brisco MA, Kimmel SE, Coca SG, Putt ME, Jessup M, Tang WW, et al. Prevalence and 
prognostic importance of changes in renal function after mechanical circulatory support. 
Circ Heart Fail. 2014;7:68–75.  
20. Testani J, McCauley B, Kimmel S, Shannon R. Characteristics of patients with 
improvement or worsening in renal function during treatment of acute decompensated 
heart failure. Am J Cardiol. 2010;106:1763–9.  
21. Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015; 36: 
1437-44.  
22. Weatherley BD, Cotter G, Dittrich HC, DeLucca P, Mansoor GA, Bloomfield DM, 
Ponikowski P, O'Connor CM, Metra M, Massie BM. Design and rationale of the 
PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine 
receptor antagonist rolofylline for patients hospitalized with acute decompensated heart 
failure and volume overload to assess treatment effect on congestion and renal function. J 
Card Fail 2010; 16: 25-35.  
23. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley 
BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, 
Bloomfield DM, Dittrich HC, Investigators P, Committees. Rolofylline, an adenosine 
A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363: 1419-28.  
24. Givertz MM1, Postmus D, Hillege HL, Mansoor GA, Massie BM, Davison BA, 
Ponikowski P, Metra M, Teerlink JR, Cleland JG, Dittrich HC, O'Connor CM, Cotter G, 
Voors AA. Renal function trajectories and clinical outcomes in acute heart failure. Circ 
Heart Fail. 2014; 7: 59-67.  
  
25. Voors AA, Dittrich HC, Massie BM, DeLucca P, Mansoor GA, Metra M, Cotter G, 
Weatherley BD, Ponikowski P, Teerlink JR, Cleland JG, O'Connor CM, Givertz MM. 
Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients 
with acute heart failure and renal dysfunction: results from PROTECT (Placebo-
Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist 
Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and 
Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am 
Coll Cardiol. 2011; 57: 1899-907. 
26. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, 
Cook T, Swedberg K, Burnett JC Jr, Grinfeld L, Udelson JE, Zannad F, Gheorghiade M; 
EVEREST Trial Investigators. Clinical course and predictive value of congestion during 
hospitalization in patients admitted for worsening signs and symptoms of heart failure 
with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013; 34: 
835-43. 
27. Cleland JG, Chiswell K, Teerlink JR, Stevens S, Fiuzat M, Givertz MM, Davison BA, 
Mansoor GA, Ponikowski P, Voors AA, Cotter G, Metra M, Massie BM, O'Connor CM. 
Predictors of postdischarge outcomes from information acquired shortly after admission 
for acute heart failure: a report from the Placebo-Controlled Randomized Study of the 
Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With 
Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect 
on Congestion and Renal Function (PROTECT) Study. Circ Heart Fail. 2014; 7: 76-87.  
28. Davison BA, Metra M, Senger S, Edwards C, Milo O, Bloomfield DM, Cleland JG, 
Dittrich HC, Givertz MM, O'Connor CM, Massie BM, Ponikowski P, Teerlink JR, Voors 
  
AA, Cotter G. Patient journey after admission for acute heart failure: length of stay, 30-
day readmission and 90-day mortality. Eur J Heart Fail. 2016; 18: 1041-50. 
29. Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and 
some applications. Stat Med. 1991; 10: 585-98. 
30. Breidthardt T, Weidmann ZM, Twerenbold R, Gantenbein C, Stallone F, Rentsch K, 
Rubini Gimenez M, Kozhuharov N, Sabti Z, Breitenbücher D, Wildi K, Puelacher C, 
Honegger U, Wagener M, Schumacher C, Hillinger P, Osswald S, Mueller C. Impact of 
haemoconcentration during acute heart failure therapy on mortality and its relationship 
with worsening renal function. Eur J Heart Fail. 2017;19:226-236. 
 
 
  
 
Clinical perspective:  
The importance of an increase in serum creatinine, traditionally considered as worsening renal function (WRF), during an admission 
for acute heart failure (AHF) has been recently debated, with data suggesting an interaction between congestion and creatinine 
changes. In a post-hoc analysis, we analysed the association of WRF with length of hospital stay, 30-day death or cardiovascular 
(CV)/renal re-admission and 90-day mortality in the PROTECT study. Daily creatinine changes from baseline were categorized as 
representing WRF (an increase of 0.3 mg/dL or more) or not. Congestion scores were computed for each study day by summing the 
coded values of orthopnea, edema and jugular venous pressure. We have found pts with WRF and consetsion had longer LOS - 3.51 
(95% CI 1.29-5.73) more days (p=0.0019), more HF hospitalization was 1.49 (95% CI 1.06-2.09) times higher (p=0.0205), with a 
similar trend was observed with 90-day mortality although this did not reach statistical significance.  Hence, in patients admitted for 
AHF, WRF as determined by a creatinine increase of ≥0.3 mg/dL was associated with longer LOS, and worse outcomes at 30 and 90 
days. However, these effects were largely driven by patients who had residual congestion at the time of renal function assessment.  
 
 
  
Table 1: Baseline characteristics by creatinine increase from baseline and congestion score at Day 2 
 
Parameter 
Creatinine increase < 0.3 
mg/dL and congestion 
score ≤  2 (N=386) 
Creatinine increase < 0.3 
mg/dL and congestion 
score ≥  3 (N=1161) 
Creatinine increase ≥  0.3 
mg/dL and congestion 
score ≤  2 (N=45) 
Creatinine increase ≥  0.3 
mg/dL and congestion 
score ≥  3 (N=92) P-value 
Age, y 70.3 (11.83) 69.8 (11.58) 71.0 (10.19) 71.5 (10.80) 0.5081 
Male gender 267 (69.2%) 768 (66.1%) 30 (66.7%) 58 (63.0%) 0.6209 
White race 372 (96.4%) 1090 (94.8%) 43 (97.7%) 90 (97.8%) 0.3074 
Time from presentation to randomization, h 16.40 (6.25, 21.60) 17.10 (5.40, 21.60) 16.15 (5.65, 23.35) 16.35 (5.20, 22.30) 0.9548 
History of ischemic heart disease 251 (65.2%) 817 (70.5%) 31 (68.9%) 60 (65.2%) 0.2194 
History of angina 64 (16.6%) 260 (22.5%) 15 (33.3%) 26 (28.3%) 0.0065 
History of previous stroke or PVD 66 (17.1%) 204 (17.6%) 15 (33.3%) 22 (23.9%) 0.0228 
History of diabetes mellitus 153 (39.7%) 549 (47.3%) 20 (44.4%) 33 (35.9%) 0.0199 
History of respiratory disease 72 (18.7%) 240 (20.7%) 8 (17.8%) 19 (20.7%) 0.8107 
History of mitral regurgitation 135 (35.0%) 401 (34.6%) 14 (31.1%) 30 (32.6%) 0.9358 
History of atrial fibrillation/flutter 193 (50.3%) 642 (55.8%) 20 (44.4%) 44 (47.8%) 0.0806 
History of chronic heart failure 361 (93.5%) 1122 (96.6%) 40 (88.9%) 88 (95.7%) 0.0077 
History of hypertension 293 (75.9%) 932 (80.3%) 35 (77.8%) 78 (84.8%) 0.1623 
History of hyperlipidemia 211 (54.7%) 598 (51.6%) 26 (57.8%) 49 (53.3%) 0.6445 
History of smoking 82 (21.3%) 258 (22.3%) 9 (20.0%) 14 (15.2%) 0.4573 
History of CABG or PCI 146 (38.0%) 452 (39.2%) 22 (48.9%) 30 (32.6%) 0.3094 
Heart failure hospitalization in previous year 179 (46.4%) 600 (51.7%) 19 (42.2%) 43 (46.7%) 0.1855 
NYHA class in previous month      
None/I/II 111 (28.8%) 215 (18.5%) 13 (28.9%) 23 (25.3%) <.0001 
III 203 (52.6%) 558 (48.1%) 22 (48.9%) 41 (45.1%)  
IV 72 (18.7%) 388 (33.4%) 10 (22.2%) 27 (29.7%)  
Body mass index, kg/m2 26.74 (23.72, 29.40) 28.12 (24.53, 32.79) 25.95 (24.28, 28.07) 28.00 (24.98, 31.53) <.0001 
Ejection fraction, % 30.0 (23.0, 40.0) 30.0 (21.0, 40.0) 35.0 (33.0, 40.0) 27.0 (20.0, 45.0) 0.0265 
Heart rate, bpm 79.3 (15.13) 80.3 (15.60) 77.6 (14.13) 81.0 (14.11) 0.4369 
Systolic blood pressure, mmHg 123.1 (17.51) 123.9 (17.36) 128.2 (17.61) 126.6 (18.32) 0.1235 
Diastolic blood pressure, mmHg 72.6 (11.98) 74.0 (11.39) 72.3 (11.69) 75.6 (11.85) 0.0661 
Pulse pressure, mmHg 50.5 (14.96) 49.9 (15.00) 55.9 (14.83) 51.1 (15.67) 0.0590 
Mean arterial pressure, mmHg 89.46 (12.171) 90.64 (11.707) 90.96 (12.065) 92.59 (12.284) 0.1083 
Respiratory rate, breaths per min 20.9 (4.20) 21.3 (4.20) 19.3 (2.99) 22.2 (4.65) 0.0008 
Edema      
0 125 (32.4%) 92 (7.9%) 17 (37.8%) 12 (13.0%) <.0001 
>1 114 (29.5%) 160 (13.8%) 17 (37.8%) 23 (25.0%)  
>2 130 (33.7%) 501 (43.2%) 9 (20.0%) 39 (42.4%)  
>3 17 (4.4%) 408 (35.1%) 2 (4.4%) 18 (19.6%)  
Jugular venous pressure      
<6 cm 91 (23.8%) 89 (7.7%) 11 (25.0%) 8 (8.8%) <.0001 
  
Parameter 
Creatinine increase < 0.3 
mg/dL and congestion 
score ≤  2 (N=386) 
Creatinine increase < 0.3 
mg/dL and congestion 
score ≥  3 (N=1161) 
Creatinine increase ≥  0.3 
mg/dL and congestion 
score ≤  2 (N=45) 
Creatinine increase ≥  0.3 
mg/dL and congestion 
score ≥  3 (N=92) P-value 
6-10 cm 209 (54.6%) 510 (44.2%) 28 (63.6%) 43 (47.3%)  
>10 cm 83 (21.7%) 556 (48.1%) 5 (11.4%) 40 (44.0%)  
Orthopnea      
None 33 (8.7%) 24 (2.1%) 6 (13.3%) 4 (4.3%) <.0001 
1 pillow 84 (22.2%) 92 (8.0%) 16 (35.6%) 6 (6.5%)  
2 pillows 165 (43.5%) 457 (39.9%) 13 (28.9%) 40 (43.5%)  
>30° 97 (25.6%) 573 (50.0%) 10 (22.2%) 42 (45.7%)  
Rales      
0 35 (9.1%) 111 (9.6%) 8 (17.8%) 10 (10.9%) 0.0971 
<1/3 123 (31.9%) 350 (30.2%) 9 (20.0%) 23 (25.0%)  
1/3 to 2/3 202 (52.3%) 570 (49.2%) 26 (57.8%) 47 (51.1%)  
>2/3 26 (6.7%) 128 (11.0%) 2 (4.4%) 12 (13.0%)  
Hemoglobin, g/dL 12.87 (1.987) 12.59 (1.961) 12.61 (1.978) 12.37 (2.105) 0.0819 
White blood cell count, x109/L 7.63 (6.28, 9.49) 7.32 (5.99, 9.10) 8.33 (7.27, 9.24) 7.89 (6.19, 9.93) 0.0195 
Sodium, mEq/L 139.5 (3.82) 139.2 (4.18) 139.5 (3.40) 139.2 (4.27) 0.6775 
Potassium, mEq/L 4.26 (0.571) 4.26 (0.580) 4.35 (0.605) 4.33 (0.545) 0.5116 
Bicarbonate, mEq/L 23.9 (3.67) 24.0 (3.78) 23.2 (3.80) 23.0 (4.02) 0.0472 
Creatinine, mg/dL 1.40 (1.10, 1.70) 1.40 (1.10, 1.80) 1.50 (1.20, 2.10) 1.55 (1.25, 1.90) 0.0071 
eGFR, mL/min 48.95 (17.107) 49.04 (18.801) 44.61 (20.740) 41.99 (16.415) 0.0020 
BUN, mg/dL 28.0 (22.0, 38.0) 29.0 (22.0, 41.0) 30.0 (23.0, 43.0) 34.0 (24.5, 48.0) 0.0283 
BUN/creatinine ratio 21.93 (6.773) 22.73 (7.339) 20.63 (6.074) 22.65 (7.621) 0.0810 
Uric acid, mg/dL 515.73 (150.010) 541.33 (151.949) 475.70 (112.710) 509.68 (154.683) 0.0009 
Albumin, g/dL 3.94 (0.408) 3.82 (0.430) 3.92 (0.428) 3.87 (0.517) <.0001 
ALT, U/L 22.0 (15.5, 33.0) 21.0 (15.0, 30.0) 16.0 (11.0, 26.0) 20.0 (13.0, 32.0) 0.0267 
Glucose, mg/dL 6.83 (5.61, 8.71) 7.02 (5.72, 9.10) 6.60 (5.38, 8.38) 6.83 (5.72, 8.38) 0.2077 
Cholesterol, mg/dL 3.99 (1.193) 3.67 (1.054) 4.30 (1.082) 4.09 (1.423) <.0001 
Triglycerides, mg/dL 95.0 (66.0, 135.0) 87.0 (65.0, 118.0) 102.0 (68.0, 145.0) 75.5 (58.5, 126.5) 0.0164 
  
ALT, alanine transferase; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association; 
PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; Q1, first quartile; Q3, third quartile. 
Summary statistics based on subjects who were followed up beyond Day 2 and had creatinine increase from baseline and congestion score available for that study day. 
Results shown are mean (standard deviation) with p-value from ANOVA (F-test) for continuous variables, median (first and third quartile) with p-value from Kruskal-Wallis 
test for continuous variables with skewed distributions, or prevalence (%) with p-value from Chi-squared test for categorical variables. 
  
Table 2: Baseline characteristics by creatinine increase from baseline and congestion score at Day 14 
 
Parameter 
Creatinine increase < 0.3 
mg/dL and congestion 
score ≤  2 (N=902) 
Creatinine increase < 0.3 
mg/dL and congestion 
score ≥  3 (N=281) 
Creatinine increase ≥  0.3 
mg/dL and congestion 
score ≤  2 (N=249) 
Creatinine increase ≥  0.3 
mg/dL and congestion 
score ≥  3 (N=105) P-value 
Age, y 69.1 (11.72) 71.2 (11.07) 72.0 (10.98) 70.5 (11.08) 0.0011 
Male gender 593 (65.7%) 193 (68.7%) 159 (63.9%) 76 (72.4%) 0.3563 
White race 870 (97.0%) 253 (90.7%) 240 (96.8%) 94 (90.4%) <.0001 
Time from presentation to randomization, h 17.20 (5.75, 21.70) 17.10 (5.50, 21.80) 14.35 (4.65, 20.80) 17.10 (4.75, 21.75) 0.1102 
History of ischemic heart disease 610 (67.7%) 196 (69.8%) 180 (72.3%) 79 (75.2%) 0.2730 
History of angina 216 (23.9%) 38 (13.6%) 56 (22.5%) 22 (21.2%) 0.0036 
History of previous stroke or PVD 141 (15.6%) 54 (19.2%) 59 (23.7%) 21 (20.0%) 0.0234 
History of diabetes mellitus 370 (41.1%) 164 (58.4%) 108 (43.4%) 55 (52.4%) <.0001 
History of respiratory disease 163 (18.1%) 54 (19.4%) 63 (25.3%) 30 (28.8%) 0.0094 
History of mitral regurgitation 302 (33.6%) 98 (34.9%) 81 (32.5%) 34 (32.7%) 0.9461 
History of atrial fibrillation/flutter 475 (53.1%) 161 (57.9%) 128 (51.6%) 59 (56.7%) 0.4127 
History of chronic heart failure 861 (95.5%) 277 (98.6%) 232 (93.2%) 102 (97.1%) 0.0160 
History of hypertension 694 (76.9%) 226 (80.4%) 204 (81.9%) 96 (91.4%) 0.0032 
History of hyperlipidemia 416 (46.1%) 173 (61.8%) 142 (57.0%) 74 (70.5%) <.0001 
History of smoking 182 (20.2%) 68 (24.3%) 52 (21.0%) 31 (29.5%) 0.1043 
History of CABG or PCI 294 (32.8%) 133 (47.5%) 108 (43.5%) 58 (55.2%) <.0001 
Heart failure hospitalization in previous year 433 (48.0%) 143 (50.9%) 119 (47.8%) 65 (61.9%) 0.0509 
NYHA class in previous month      
None/I/II 172 (19.1%) 46 (16.4%) 75 (30.1%) 27 (25.7%) <.0001 
III 420 (46.6%) 166 (59.3%) 111 (44.6%) 57 (54.3%)  
IV 310 (34.4%) 68 (24.3%) 63 (25.3%) 21 (20.0%)  
Body mass index, kg/m2 27.05 (23.99, 30.80) 29.33 (25.64, 33.64) 26.95 (23.81, 30.63) 29.98 (26.67, 34.52) <.0001 
Ejection fraction, % 30.0 (22.0, 38.0) 29.0 (20.0, 40.0) 34.5 (21.0, 45.0) 27.0 (20.0, 45.0) 0.2256 
Heart rate, bpm 81.6 (15.76) 77.7 (14.91) 77.4 (14.66) 77.1 (14.03) <.0001 
Systolic blood pressure, mmHg 124.2 (16.36) 122.3 (18.27) 127.0 (18.96) 121.9 (18.51) 0.0082 
Diastolic blood pressure, mmHg 74.7 (10.87) 71.8 (13.33) 73.6 (12.05) 70.5 (11.26) <.0001 
Pulse pressure, mmHg 49.4 (13.99) 50.5 (15.47) 53.5 (16.68) 51.4 (17.08) 0.0020 
Mean arterial pressure, mmHg 91.20 (11.154) 88.63 (13.287) 91.39 (12.441) 87.61 (11.571) 0.0005 
Respiratory rate, breaths per min 21.4 (4.13) 21.3 (3.87) 21.2 (4.20) 20.6 (3.72) 0.3898 
Edema      
0 155 (17.2%) 19 (6.8%) 45 (18.1%) 4 (3.8%) <.0001 
>1 172 (19.1%) 44 (15.7%) 55 (22.1%) 15 (14.3%)  
>2 382 (42.4%) 108 (38.4%) 94 (37.8%) 39 (37.1%)  
>3 193 (21.4%) 110 (39.1%) 55 (22.1%) 47 (44.8%)  
Jugular venous pressure      
<6 cm 115 (12.9%) 19 (7.0%) 41 (16.7%) 7 (7.0%) 0.0003 
  
Parameter 
Creatinine increase < 0.3 
mg/dL and congestion 
score ≤  2 (N=902) 
Creatinine increase < 0.3 
mg/dL and congestion 
score ≥  3 (N=281) 
Creatinine increase ≥  0.3 
mg/dL and congestion 
score ≤  2 (N=249) 
Creatinine increase ≥  0.3 
mg/dL and congestion 
score ≥  3 (N=105) P-value 
6-10 cm 435 (48.9%) 120 (44.3%) 116 (47.2%) 40 (40.0%)  
>10 cm 340 (38.2%) 132 (48.7%) 89 (36.2%) 53 (53.0%)  
Orthopnea      
None 31 (3.5%) 11 (4.0%) 13 (5.3%) 3 (2.9%) <.0001 
1 pillow 118 (13.2%) 11 (4.0%) 32 (13.1%) 7 (6.9%)  
2 pillows 400 (44.6%) 110 (40.0%) 95 (38.8%) 32 (31.4%)  
>30° 347 (38.7%) 143 (52.0%) 105 (42.9%) 60 (58.8%)  
Rales      
0 77 (8.6%) 35 (12.5%) 27 (10.8%) 12 (11.4%) 0.2185 
<1/3 266 (29.6%) 89 (31.8%) 67 (26.9%) 37 (35.2%)  
1/3 to 2/3 469 (52.1%) 125 (44.6%) 136 (54.6%) 48 (45.7%)  
>2/3 88 (9.8%) 31 (11.1%) 19 (7.6%) 8 (7.6%)  
Hemoglobin, g/dL 13.00 (2.024) 12.32 (1.775) 12.34 (1.839) 11.57 (1.565) <.0001 
White blood cell count, x109/L 7.48 (6.08, 9.25) 7.29 (6.04, 9.04) 7.52 (6.20, 9.06) 6.97 (5.37, 8.64) 0.0500 
Sodium, mEq/L 139.6 (3.90) 138.6 (4.24) 139.8 (3.97) 138.9 (3.65) 0.0006 
Potassium, mEq/L 4.29 (0.563) 4.24 (0.599) 4.20 (0.620) 4.24 (0.511) 0.1232 
Bicarbonate, mEq/L 23.8 (3.62) 24.4 (3.83) 24.0 (3.72) 23.6 (4.05) 0.0729 
Creatinine, mg/dL 1.30 (1.10, 1.70) 1.40 (1.20, 1.90) 1.30 (1.10, 1.70) 1.60 (1.30, 2.20) <.0001 
eGFR, mL/min 50.62 (18.756) 46.75 (17.936) 49.19 (19.600) 40.24 (14.716) <.0001 
BUN, mg/dL 27.0 (21.0, 38.0) 33.0 (23.0, 48.0) 29.0 (22.0, 38.0) 36.0 (27.0, 50.0) <.0001 
BUN/creatinine ratio 21.70 (6.513) 24.19 (8.237) 21.77 (6.704) 23.66 (8.348) <.0001 
Uric acid, mg/dL 528.04 (146.107) 551.09 (154.374) 500.03 (146.119) 575.03 (160.030) <.0001 
Albumin, g/dL 3.89 (0.439) 3.81 (0.419) 3.85 (0.413) 3.84 (0.424) 0.0430 
ALT, U/L 22.0 (15.0, 34.0) 19.0 (15.0, 29.0) 20.0 (14.0, 30.0) 18.0 (12.0, 24.5) <.0001 
Glucose, mg/dL 6.99 (5.72, 8.99) 7.22 (5.86, 9.82) 6.83 (5.72, 8.52) 6.83 (5.61, 8.10) 0.0302 
Cholesterol, mg/dL 3.94 (1.133) 3.47 (1.016) 3.92 (1.124) 3.41 (1.026) <.0001 
Triglycerides, mg/dL 90.0 (66.0, 125.0) 84.0 (65.0, 117.0) 89.0 (65.0, 130.0) 81.0 (62.0, 112.0) 0.1655 
  
ALT, alanine transferase; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association; 
PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; Q1, first quartile; Q3, third quartile. 
Summary statistics based on subjects who were followed up beyond Day 14 and had creatinine increase from baseline and congestion score available for that study day. 
Results shown are mean (standard deviation) with p-value from ANOVA (F-test) for continuous variables, median (first and third quartile) with p-value from Kruskal-Wallis 
test for continuous variables with skewed distributions, or prevalence (%) with p-value from Chi-squared test for categorical variables. 
 
  
Figure 1: Adjusted associations of creatinine increase from baseline with all-cause death or CV/RF rehospitalization through 30 days after Day x by congestion 
score 
 
Study day refers to the day of serum creatinine measurement and congestion score assessment (with baseline at Day 1). Adjusted hazard ratios for the effect of creatinine 
increase with 95% confidence intervals were estimated from Cox proportional hazards models for each study day that included the effects of creatinine increase, congestion 
category, and their interaction, in subjects who were followed up beyond Days 2, 3, 4, 5, 7, or 14, respectively, and had creatinine change from baseline and congestion 
score available for that study day. Log hazard ratios > 0 correspond to hazard ratios > 1 and signify a harmful effect of creatinine increase. The ratio of the creatinine 
effects between the congestion categories was estimated based on 1000 bootstrap samples and a linear regression model including congestion score and time. The 
congestion-by-time interaction p-value was estimated from a model that also included the interaction effect. 
 
 
 
  
Figure 2: Adjusted associations of creatinine increase from baseline with all-cause mortality through Day 90 by congestion score 
 
Study day refers to the day of serum creatinine measurement and congestion score assessment (with baseline at Day 1). Adjusted hazard ratios for the effect of creatinine 
increase with 95% confidence intervals were estimated from Cox proportional hazards models for each study day that included the effects of creatinine increase, congestion 
category, and their interaction, in subjects who were followed up beyond Days 2, 3, 4, 5, 7, or 14, respectively, and had creatinine change from baseline and congestion 
score available for that study day. Log hazard ratios > 0 correspond to hazard ratios > 1 and signify a harmful effect of creatinine increase. The ratio of the creatinine 
effects between the congestion categories was estimated based on 1000 bootstrap samples and a linear regression model including congestion score and time. The 
congestion-by-time interaction p-value was estimated from a model that also included the interaction effect. 
 
 
 
  
Figure 3a: Adjusted associations of creatinine increase from baseline with length of in-hospital stay through Day 60 by congestion score 
 
 
Study day refers to the day of serum creatinine measurement and congestion score assessment (with baseline at Day 1). Adjusted mean differences for the effect of 
creatinine increase with 95% confidence intervals were estimated from linear regression models for each study day that included the effects of creatinine increase, 
congestion category, and their interaction, in subjects who were followed up beyond Days 2, 3, 4, 5, or 7, respectively, and had creatinine change from baseline and 
congestion score available for that study day. Mean differences > 0 signify a longer LOS in patients with a creatinine increase. The difference in creatinine effects between 
the congestion categories was estimated based on 1000 bootstrap samples and a linear regression model including congestion score and time. The congestion-by-time 
interaction p-value was estimated from a model that also included the interaction effect. 
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Supplemental Table 1a: Unadjusted and adjusted associations of creatinine increase from baseline with all-cause death or CV/RF rehospitalization through 30 
days after Day x by congestion score 
 
 Univariable model Multivariable model † 
Parameter Category 
Sample size per 
category / total 
Hazard ratio 
(95% CI) 
Interaction 
p-value # 
Hazard ratio 
(95% CI) 
Interaction 
p-value # 
Creatinine increase ≥  0.3 mg/dL at Day 2 Congestion score ≤  2 at Day 2  431 / 1684 0.90 (0.39, 2.09) 0.1433 0.93 (0.40, 2.18) 0.2071 
 Congestion score ≥  3 at Day 2 1253 / 1684 1.81 (1.21, 2.73)  1.71 (1.13, 2.59)  
  
Creatinine increase ≥  0.3 mg/dL at Day 3 Congestion score ≤  2 at Day 3  805 / 1666 1.17 (0.77, 1.79) 0.8916 1.16 (0.76, 1.78) 0.9287 
 Congestion score ≥  3 at Day 3  861 / 1666 1.12 (0.72, 1.75)  1.19 (0.76, 1.86)  
  
Creatinine increase ≥  0.3 mg/dL at Day 4 Congestion score ≤  2 at Day 4  885 / 1506 0.97 (0.63, 1.48) 0.0662 1.00 (0.65, 1.53) 0.2175 
 Congestion score ≥  3 at Day 4  621 / 1506 1.68 (1.12, 2.54)  1.45 (0.95, 2.21)  
  
Creatinine increase ≥  0.3 mg/dL at Day 5 Congestion score ≤  2 at Day 5  863 / 1296 0.81 (0.51, 1.30) 0.0068 0.72 (0.45, 1.15) 0.0065 
 Congestion score ≥  3 at Day 5  433 / 1296 2.00 (1.27, 3.16)  1.79 (1.13, 2.85)  
  
Creatinine increase ≥  0.3 mg/dL at Day 6/7 Congestion score ≤  2 at Day 6/7 1178 / 1612 1.12 (0.79, 1.60) 0.3453 1.02 (0.71, 1.47) 0.3642 
 Congestion score ≥  3 at Day 6/7  434 / 1612 1.46 (0.97, 2.18)  1.32 (0.87, 1.99)  
  
Creatinine increase ≥  0.3 mg/dL at Day 14 Congestion score ≤  2 at Day 14 1116 / 1477 1.04 (0.70, 1.54) 0.2592 1.00 (0.68, 1.49) 0.2336 
 Congestion score ≥  3 at Day 14  361 / 1477 1.44 (0.96, 2.15)  1.42 (0.94, 2.14)  
  
CI, confidence interval. 
Results from Cox proportional hazards models including interaction term based on subjects who were followed up beyond Days 2, 3, 4, 5, 7, or 14, respectively, and had 
creatinine increase from baseline and congestion score available for that study day. Hazard ratios presented for creatinine increase from baseline 'Yes vs. No'. 
† Estimated effect sizes adjusted for baseline variables age, heart failure hospitalization in previous year, NYHA class in previous month, ischemic heart disease, body mass 
index, edema, rales, systolic blood pressure, albumin, BUN, and sodium (Cleland et al., 2014). 
# For the interaction of creatinine increase from baseline and congestion score. 
 
  
 
Supplemental Table 1b: Unadjusted and adjusted associations of creatinine increase from baseline with all-cause death or CV/RF rehospitalization through 30 
days after Day x by the previous day’s congestion score 
 
 Univariable model Multivariable model † 
Parameter Category 
Sample size per 
category / total 
Hazard ratio 
(95% CI) 
Interaction 
p-value # 
Hazard ratio 
(95% CI) 
Interaction 
p-value # 
Creatinine increase ≥  0.3 mg/dL at Day 2 Congestion score ≤  2 prior Day 2   71 / 1690 1.47 (0.41, 5.20) 0.9626 2.44 (0.68, 8.82) 0.4622 
 Congestion score ≥  3 prior Day 2 1619 / 1690 1.52 (1.03, 2.23)  1.48 (1.00, 2.19)  
  
Creatinine increase ≥  0.3 mg/dL at Day 3 Congestion score ≤  2 prior Day 3  427 / 1660 1.12 (0.61, 2.06) 0.9186 1.18 (0.64, 2.18) 0.9708 
 Congestion score ≥  3 prior Day 3 1233 / 1660 1.16 (0.82, 1.65)  1.16 (0.81, 1.66)  
  
Creatinine increase ≥  0.3 mg/dL at Day 4 Congestion score ≤  2 prior Day 4  703 / 1510 1.02 (0.65, 1.59) 0.1308 1.02 (0.65, 1.61) 0.2462 
 Congestion score ≥  3 prior Day 4  807 / 1510 1.60 (1.10, 2.34)  1.44 (0.98, 2.12)  
  
Creatinine increase ≥  0.3 mg/dL at Day 5 Congestion score ≤  2 prior Day 5  753 / 1300 0.97 (0.61, 1.54) 0.1273 0.89 (0.55, 1.42) 0.1427 
 Congestion score ≥  3 prior Day 5  547 / 1300 1.59 (1.03, 2.45)  1.44 (0.92, 2.24)  
  
Creatinine increase ≥  0.3 mg/dL at Day 6/7 Congestion score ≤  2 prior Day 6/7  883 / 1333 1.02 (0.68, 1.54) 0.0691 0.88 (0.58, 1.34) 0.0438 
 Congestion score ≥  3 prior Day 6/7  450 / 1333 1.78 (1.15, 2.76)  1.64 (1.05, 2.56)  
  
CI, confidence interval. 
Results from Cox proportional hazards models including interaction term based on subjects who were followed up beyond Days 2, 3, 4, 5, 7, or 14, respectively, and had 
creatinine increase from baseline and congestion score available for that study day. Hazard ratios presented for creatinine increase from baseline 'Yes vs. No'. 
† Estimated effect sizes adjusted for baseline variables age, heart failure hospitalization in previous year, NYHA class in previous month, ischemic heart disease, body mass 
index, edema, rales, systolic blood pressure, albumin, BUN, and sodium (Cleland et al., 2014). 
# For the interaction of creatinine increase from baseline and congestion score. 
 
  
Supplemental Table 2a: Unadjusted and adjusted associations of creatinine increase from baseline with all-cause mortality through Day 90 by congestion score 
 
 Univariable model Multivariable model † 
Parameter Category 
Sample size per 
category / total 
Hazard ratio 
(95% CI) 
Interaction 
p-value # 
Hazard ratio 
(95% CI) 
Interaction 
p-value # 
Creatinine increase ≥  0.3 mg/dL at Day 2 Congestion score ≤  2 at Day 2  431 / 1684 0.87 (0.27, 2.87) 0.3171 1.04 (0.32, 3.45) 0.4971 
 Congestion score ≥  3 at Day 2 1253 / 1684 1.69 (1.02, 2.79)  1.64 (0.98, 2.74)  
  
Creatinine increase ≥  0.3 mg/dL at Day 3 Congestion score ≤  2 at Day 3  805 / 1667 1.29 (0.73, 2.29) 0.6651 1.56 (0.87, 2.80) 0.9323 
 Congestion score ≥  3 at Day 3  862 / 1667 1.52 (0.95, 2.41)  1.61 (1.00, 2.59)  
  
Creatinine increase ≥  0.3 mg/dL at Day 4 Congestion score ≤  2 at Day 4  885 / 1506 0.76 (0.39, 1.49) 0.0309 0.92 (0.46, 1.81) 0.0900 
 Congestion score ≥  3 at Day 4  621 / 1506 1.85 (1.18, 2.88)  1.86 (1.17, 2.96)  
  
Creatinine increase ≥  0.3 mg/dL at Day 5 Congestion score ≤  2 at Day 5  864 / 1297 1.36 (0.77, 2.39) 0.3512 1.44 (0.81, 2.55) 0.5194 
 Congestion score ≥  3 at Day 5  433 / 1297 1.93 (1.21, 3.08)  1.84 (1.13, 2.99)  
  
Creatinine increase ≥  0.3 mg/dL at Day 6/7 Congestion score ≤  2 at Day 6/7 1187 / 1624 1.38 (0.86, 2.23) 0.3938 1.48 (0.91, 2.40) 0.3462 
 Congestion score ≥  3 at Day 6/7  437 / 1624 1.86 (1.16, 2.98)  2.05 (1.26, 3.32)  
  
Creatinine increase ≥  0.3 mg/dL at Day 14 Congestion score ≤  2 at Day 14 1151 / 1537 1.18 (0.67, 2.07) 0.0504 1.16 (0.65, 2.06) 0.0696 
 Congestion score ≥  3 at Day 14  386 / 1537 2.59 (1.49, 4.49)  2.43 (1.39, 4.27)  
  
CI, confidence interval. 
Results from Cox proportional hazards models including interaction term based on subjects who were followed up beyond Days 2, 3, 4, 5, 7, or 14, respectively, and had 
creatinine increase from baseline and congestion score available for that study day. Hazard ratios presented for creatinine increase from baseline 'Yes vs. No'. 
† Estimated effect sizes adjusted for baseline variables age, heart failure hospitalization in previous year, NYHA class in previous month, rales, systolic blood pressure, 
albumin, bicarbonate, BUN, creatinine, glucose, and sodium (Cleland et al., 2014). 
# For the interaction of creatinine increase from baseline and congestion score. 
 
  
 
 
Supplemental Table 2b: Unadjusted and adjusted associations of creatinine increase from baseline with all-cause mortality through Day 90 by the previous day’s 
congestion score 
 
 Univariable model Multivariable model † 
Parameter Category 
Sample size per 
category / total 
Hazard ratio 
(95% CI) 
Interaction 
p-value # 
Hazard ratio 
(95% CI) 
Interaction 
p-value # 
Creatinine increase ≥  0.3 mg/dL at Day 2 Congestion score ≤  2 prior Day 2   71 / 1690 0.00 (0.00, Inf.) 0.9727 0.00 (0.00, Inf.) 0.9768 
 Congestion score ≥  3 prior Day 2 1619 / 1690 1.51 (0.95, 2.40)  1.55 (0.96, 2.50)  
  
Creatinine increase ≥  0.3 mg/dL at Day 3 Congestion score ≤  2 prior Day 3  427 / 1661 0.76 (0.29, 1.99) 0.1582 1.00 (0.38, 2.62) 0.3278 
 Congestion score ≥  3 prior Day 3 1234 / 1661 1.61 (1.09, 2.37)  1.68 (1.12, 2.52)  
  
Creatinine increase ≥  0.3 mg/dL at Day 4 Congestion score ≤  2 prior Day 4  703 / 1510 0.88 (0.46, 1.70) 0.0958 1.12 (0.57, 2.18) 0.2823 
 Congestion score ≥  3 prior Day 4  807 / 1510 1.72 (1.12, 2.67)  1.73 (1.11, 2.70)  
  
Creatinine increase ≥  0.3 mg/dL at Day 5 Congestion score ≤  2 prior Day 5  754 / 1301 1.70 (0.95, 3.03) 0.9886 1.76 (0.98, 3.18) 0.9794 
 Congestion score ≥  3 prior Day 5  547 / 1301 1.69 (1.08, 2.63)  1.75 (1.10, 2.76)  
  
Creatinine increase ≥  0.3 mg/dL at Day 6/7 Congestion score ≤  2 prior Day 6/7  885 / 1335 1.54 (0.90, 2.62) 0.4537 1.77 (1.02, 3.06) 0.5557 
 Congestion score ≥  3 prior Day 6/7  450 / 1335 2.00 (1.28, 3.14)  2.19 (1.38, 3.48)  
  
CI, confidence interval. 
Results from Cox proportional hazards models including interaction term based on subjects who were followed up beyond Days 2, 3, 4, 5, 7, or 14, respectively, and had 
creatinine increase from baseline and congestion score available for that study day. Hazard ratios presented for creatinine increase from baseline 'Yes vs. No'. 
† Estimated effect sizes adjusted for baseline variables age, heart failure hospitalization in previous year, NYHA class in previous month, rales, systolic blood pressure, 
albumin, bicarbonate, BUN, creatinine, glucose, and sodium (Cleland et al., 2014). 
# For the interaction of creatinine increase from baseline and congestion score. 
  
Supplemental Table 3a: Unadjusted and adjusted associations of creatinine increase from baseline with length of in-hospital stay through Day 60 by congestion 
score 
 
 Univariable model Multivariable model † 
Parameter Category 
Sample size per 
category / total 
Mean difference 
(95% CI) 
Interaction 
p-value # 
Mean difference 
(95% CI) 
Interaction 
p-value # 
Creatinine increase ≥  0.3 mg/dL at Day 2 Congestion score ≤  2 at Day 2  424 / 1669 -1.73 (-5.60, 2.14) 0.0830 -0.92 (-4.49, 2.66) 0.1679 
 Congestion score ≥  3 at Day 2 1245 / 1669 2.43 (-0.24, 5.11)  2.14 (-0.35, 4.63)  
  
Creatinine increase ≥  0.3 mg/dL at Day 3 Congestion score ≤  2 at Day 3  724 / 1553 0.04 (-2.28, 2.35) 0.5388 0.42 (-1.75, 2.58) 0.3325 
 Congestion score ≥  3 at Day 3  829 / 1553 1.12 (-1.44, 3.68)  2.01 (-0.38, 4.40)  
  
Creatinine increase ≥  0.3 mg/dL at Day 4 Congestion score ≤  2 at Day 4  765 / 1330 -0.26 (-2.50, 1.97) 0.0053 0.34 (-1.79, 2.47) 0.0059 
 Congestion score ≥  3 at Day 4  565 / 1330 4.80 (2.04, 7.56)  5.09 (2.45, 7.72)  
  
Creatinine increase ≥  0.3 mg/dL at Day 5 Congestion score ≤  2 at Day 5  803 / 1217 0.02 (-2.09, 2.13) 0.0021 0.37 (-1.65, 2.39) 0.0003 
 Congestion score ≥  3 at Day 5  414 / 1217 5.68 (2.76, 8.61)  6.68 (3.87, 9.50)  
  
Creatinine increase ≥  0.3 mg/dL at Day 6/7 Congestion score ≤  2 at Day 6/7  644 / 919 -0.17 (-2.70, 2.36) 0.0268 0.13 (-2.36, 2.62) 0.0111 
 Congestion score ≥  3 at Day 6/7  275 / 919 4.68 (1.22, 8.15)  5.60 (2.18, 9.02)  
  
Creatinine increase ≥  0.3 mg/dL at Day 14 Congestion score ≤  2 at Day 14  272 / 366 3.49 (-0.48, 7.46) 0.8077 2.31 (-1.61, 6.22) 0.5208 
 Congestion score ≥  3 at Day 14   94 / 366 4.32 (-1.11, 9.75)  4.43 (-0.84, 9.70)  
  
CI, confidence interval. 
Results from linear regression models including interaction term based on subjects who were followed up beyond Days 2, 3, 4, 5, 7, or 14, respectively, stayed in hospital 
beyond that study day, had available length of stay, and had creatinine increase from baseline and congestion score available for that study day. Mean differences presented 
for creatinine increase from baseline 'Yes vs. No'. 
† Estimated effect sizes adjusted for region and baseline variables gender, history of angina, history of diabetes mellitus, history of chronic heart failure, body mass index, 
heart rate, systolic blood pressure, jugular venous pressure, orthopnea, BUN, uric acid, cholesterol, albumin, and white blood cell count (Davison et al., 2016). 
# For the interaction of creatinine increase from baseline and congestion score. 
 
 
  
 
Supplemental Table 3b: Unadjusted and adjusted associations of creatinine increase from baseline with length of in-hospital stay through Day 60 by the previous 
day’s congestion score 
 
 Univariable model Multivariable model † 
Parameter Category 
Sample size per 
category / total 
Mean difference 
(95% CI) 
Interaction 
p-value # 
Mean difference 
(95% CI) 
Interaction 
p-value # 
Creatinine increase ≥  0.3 mg/dL at Day 2 Congestion score ≤  2 prior Day 2   71 / 1677 -2.48 (-10.68, 5.71) 0.4442 0.38 (-7.10, 7.86) 0.8693 
 Congestion score ≥  3 prior Day 2 1606 / 1677 0.84 (-1.49, 3.17)  1.03 (-1.12, 3.19)  
  
Creatinine increase ≥  0.3 mg/dL at Day 3 Congestion score ≤  2 prior Day 3  370 / 1544 -2.27 (-5.46, 0.93) 0.0602 -1.58 (-4.54, 1.38) 0.0343 
 Congestion score ≥  3 prior Day 3 1174 / 1544 1.38 (-0.67, 3.43)  2.21 (0.30, 4.12)  
  
Creatinine increase ≥  0.3 mg/dL at Day 4 Congestion score ≤  2 prior Day 4  610 / 1333 0.17 (-2.28, 2.61) 0.0401 0.66 (-1.68, 3.00) 0.0443 
 Congestion score ≥  3 prior Day 4  723 / 1333 3.81 (1.34, 6.27)  4.05 (1.70, 6.41)  
  
Creatinine increase ≥  0.3 mg/dL at Day 5 Congestion score ≤  2 prior Day 5  695 / 1222 1.83 (-0.47, 4.13) 0.6379 1.73 (-0.48, 3.94) 0.2231 
 Congestion score ≥  3 prior Day 5  527 / 1222 2.67 (0.01, 5.34)  3.83 (1.25, 6.41)  
  
Creatinine increase ≥  0.3 mg/dL at Day 6/7 Congestion score ≤  2 prior Day 6/7  553 / 904 -0.71 (-3.42, 1.99) 0.0085 -0.30 (-2.96, 2.36) 0.0048 
 Congestion score ≥  3 prior Day 6/7  351 / 904 4.92 (1.73, 8.12)  5.65 (2.47, 8.83)  
  
CI, confidence interval. 
Results from linear regression models including interaction term based on subjects who were followed up beyond Days 2, 3, 4, 5, 7, or 14, respectively, stayed in hospital 
beyond that study day, had available length of stay, and had creatinine increase from baseline and congestion score available for that study day. Mean differences presented 
for creatinine increase from baseline 'Yes vs. No'. 
† Estimated effect sizes adjusted for region and baseline variables gender, history of angina, history of diabetes mellitus, history of chronic heart failure, body mass index, 
heart rate, systolic blood pressure, jugular venous pressure, orthopnea, BUN, uric acid, cholesterol, albumin, and white blood cell count (Davison et al., 2016). 
# For the interaction of creatinine increase from baseline and congestion score. 
 
  
Supplemental Table 3c: Unadjusted and adjusted associations of creatinine increase from baseline with live discharge through Day 60 by congestion score 
 
 Univariable model Multivariable model † 
Parameter Category 
Sample size per 
category / total 
Hazard ratio 
(95% CI) 
Interaction 
p-value # 
Hazard ratio 
(95% CI) 
Interaction 
p-value # 
Creatinine increase ≥  0.3 mg/dL at Day 2 Congestion score ≤  2 at Day 2  424 / 1669 1.19 (0.87, 1.63) 0.0749 1.18 (0.86, 1.61) 0.0782 
 Congestion score ≥  3 at Day 2 1245 / 1669 0.84 (0.67, 1.05)  0.83 (0.66, 1.05)  
  
Creatinine increase ≥  0.3 mg/dL at Day 3 Congestion score ≤  2 at Day 3  724 / 1553 1.00 (0.83, 1.20) 0.7581 0.87 (0.72, 1.06) 0.6735 
 Congestion score ≥  3 at Day 3  829 / 1553 0.96 (0.77, 1.18)  0.82 (0.66, 1.02)  
  
Creatinine increase ≥  0.3 mg/dL at Day 4 Congestion score ≤  2 at Day 4  765 / 1330 1.01 (0.84, 1.21) 0.0798 0.87 (0.72, 1.05) 0.0686 
 Congestion score ≥  3 at Day 4  565 / 1330 0.77 (0.61, 0.98)  0.66 (0.51, 0.83)  
  
Creatinine increase ≥  0.3 mg/dL at Day 5 Congestion score ≤  2 at Day 5  803 / 1217 1.01 (0.84, 1.20) 0.0348 0.91 (0.76, 1.09) 0.0053 
 Congestion score ≥  3 at Day 5  414 / 1217 0.71 (0.55, 0.93)  0.57 (0.44, 0.75)  
  
Creatinine increase ≥  0.3 mg/dL at Day 6/7 Congestion score ≤  2 at Day 6/7  644 / 919 1.08 (0.88, 1.32) 0.0384 1.04 (0.85, 1.28) 0.0096 
 Congestion score ≥  3 at Day 6/7  275 / 919 0.74 (0.55, 0.99)  0.64 (0.47, 0.87)  
  
Creatinine increase ≥  0.3 mg/dL at Day 14 Congestion score ≤  2 at Day 14  272 / 366 0.73 (0.52, 1.02) 0.8787 0.79 (0.56, 1.12) 0.7691 
 Congestion score ≥  3 at Day 14   94 / 366 0.76 (0.48, 1.23)  0.72 (0.44, 1.18)  
  
CI, confidence interval. 
Results from Cox proportional hazards models including interaction term based on subjects who were followed up beyond Days 2, 3, 4, 5, 7, or 14, respectively, stayed in 
hospital beyond that study day, had available length of stay, and had creatinine increase from baseline and congestion score available for that study day. Hazard ratios 
presented for creatinine increase from baseline 'Yes vs. No'. 
† Estimated effect sizes adjusted for region and baseline variables gender, history of angina, history of diabetes mellitus, history of chronic heart failure, body mass index, 
heart rate, systolic blood pressure, jugular venous pressure, orthopnea, BUN, uric acid, cholesterol, albumin, and white blood cell count (Davison et al., 2016). 
# For the interaction of creatinine increase from baseline and congestion score. 
 
  
 
  
Supplemental Figure 1: Adjusted associations of creatinine increase from baseline with all-cause death or CV/RF rehospitalization through 30 days after Day x 
by the previous day’s congestion score 
 
Sensitivity analysis: Study day refers to the day of serum creatinine measurement (with baseline at Day 1), with patient categorized by the congestion score of the 
preceding visit. Adjusted hazard ratios for the effect of creatinine increase with 95% confidence intervals were estimated from Cox proportional hazards models for each 
study day that included the effects of creatinine increase, congestion category, and their interaction, in subjects who were followed up beyond Days 2, 3, 4, 5, or 7, 
respectively, and had creatinine change from baseline and congestion score available for that study day. Log hazard ratios > 0 correspond to hazard ratios > 1 and signify a 
harmful effect of creatinine increase. The ratio of the creatinine effects between the congestion categories was estimated based on 1000 bootstrap samples and a linear 
regression model including congestion score and time. The congestion-by-time interaction p-value was estimated from a model that also included the interaction effect. 
 
 
 
  
Supplemental Figure 2: Adjusted associations of creatinine increase from baseline with all-cause mortality through Day 90 by the previous day’s congestion score 
 
Sensitivity analysis: Study day refers to the day of serum creatinine measurement (with baseline at Day 1), with patient categorized by the congestion score of the 
preceding visit. Adjusted hazard ratios for the effect of creatinine increase with 95% confidence intervals were estimated from Cox proportional hazards models for each 
study day that included the effects of creatinine increase, congestion category, and their interaction, in subjects who were followed up beyond Days 2, 3, 4, 5, or 7, 
respectively, and had creatinine change from baseline and congestion score available for that study day. Log hazard ratios > 0 correspond to hazard ratios > 1 and signify a 
harmful effect of creatinine increase. The ratio of the creatinine effects between the congestion categories was estimated based on 1000 bootstrap samples and a linear 
regression model including congestion score and time. The congestion-by-time interaction p-value was estimated from a model that also included the interaction effect. 
 
 
 
  
Supplemental Figure 3a: Adjusted associations of creatinine increase from baseline with length of in-hospital stay through Day 60 by the previous day’s 
congestion score 
 
Sensitivity analysis: Study day refers to the day of serum creatinine measurement  (with baseline at Day 1), with patients categorized by the congestion score of the 
preceding visit. Adjusted mean differences for the effect of creatinine increase with 95% confidence intervals were estimated from linear regression models for each study 
day that included the effects of creatinine increase, congestion category, and their interaction, in subjects who were followed up beyond Days 2, 3, 4, 5, or 7, respectively, 
and had creatinine change from baseline and congestion score available for that study day. Mean differences > 0 signify a longer LOS in patients with a creatinine increase. 
The difference in creatinine effects between the congestion categories was estimated based on 1000 bootstrap samples and a linear regression model including congestion 
score and time. The congestion-by-time interaction p-value was estimated from a model that also included the interaction effect. 
 
 
 
  
 
Supplemental Figure 3b: Adjusted associations of creatinine increase from baseline with live discharge through Day 60 by congestion score 
 
Sensitivity analysis: Study day refers to the day of serum creatinine measurement and congestion score assessment (with baseline at Day 1). Adjusted hazard ratios for the 
effect of creatinine increase with 95% confidence intervals were estimated from Cox proportional hazards models for each study day that included the effects of creatinine 
increase, congestion category, and their interaction, in subjects who were followed up beyond Days 2, 3, 4, 5, or 7, respectively, and had creatinine change from baseline 
and congestion score available for that study day. Log hazard ratios < 0 correspond to longer LOS in patients with a creatinine increase. The ratio of the creatinine effects 
between the congestion categories was estimated based on 1000 bootstrap samples and a linear regression model including congestion score and time. The congestion-by-
time interaction p-value was estimated from a model that also included the interaction effect. 
 
 
  
 
Supplementary Figure 4: Adjusted associations of creatinine decrease from baseline with all-cause death or CV/RF rehospitalization through 30 days after Day x 
by congestion score 
Study day refers to the day of serum creatinine measurement and congestion score assessment (with baseline at Day 1). Adjusted hazard ratios for the effect of creatinine 
decrease with 95% confidence intervals were estimated from Cox proportional hazards models for each study day that included the effects of creatinine decrease, 
congestion category, and their interaction, in subjects who were followed up beyond Days 2, 3, 4, 5, 7, or 14, respectively, and had creatinine change from baseline and 
congestion score available for that study day. Log hazard ratios > 0 correspond to hazard ratios > 1 and signify a harmful effect of creatinine decrease. The ratio of the 
creatinine effects between the congestion categories was estimated based on 1000 bootstrap samples and a linear regression model including congestion score and time. 
The congestion-by-time interaction p-value was estimated from a model that also included the interaction effect. 
 
 
 
  
Supplementary Figure 5: Adjusted associations of creatinine decrease from baseline with all-cause mortality through Day 90 by congestion score 
 
Study day refers to the day of serum creatinine measurement and congestion score assessment (with baseline at Day 1). Adjusted hazard ratios for the effect of creatinine 
decrease with 95% confidence intervals were estimated from Cox proportional hazards models for each study day that included the effects of creatinine decrease, 
congestion category, and their interaction, in subjects who were followed up beyond Days 2, 3, 4, 5, 7, or 14, respectively, and had creatinine change from baseline and 
congestion score available for that study day. Log hazard ratios > 0 correspond to hazard ratios > 1 and signify a harmful effect of creatinine decrease. The ratio of the 
creatinine effects between the congestion categories was estimated based on 1000 bootstrap samples and a linear regression model including congestion score and time. 
The congestion-by-time interaction p-value was estimated from a model that also included the interaction effect. 
 
 
 
  
Supplementary Figure 6: Adjusted associations of creatinine decrease from baseline with length of in-hospital stay through Day 60 by congestion score 
 
Study day refers to the day of serum creatinine measurement and congestion score assessment (with baseline at Day 1). Adjusted mean differences for the effect of 
creatinine decrease with 95% confidence intervals were estimated from linear regression models for each study day that included the effects of creatinine decrease, 
congestion category, and their interaction, in subjects who were followed up beyond Days 2, 3, 4, 5, 7, or 14, respectively, and had creatinine change from baseline and 
congestion score available for that study day. Mean differences > 0 correspond to longer LOS in patients with a creatinine decrease. The difference between the creatinine 
effects between the congestion categories was estimated based on 1000 bootstrap samples and a linear regression model including congestion score and time. The 
congestion-by-time interaction p-value was estimated from a model that also included the interaction effect. 
 
 
 
 
 
